Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 665Neoplasms 585Colorectal Neoplasms 291Carcinoma, Non-Small-Cell Lung 289Prostatic Neoplasms 277Lung Neoplasms 217Melanoma 159Multiple Myeloma 149Neoplasm Metastasis 145Head and Neck Neoplasms 143Pancreatic Neoplasms 139Ovarian Neoplasms 129Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 121Brain Neoplasms 111Squamous Cell Carcinoma of Head and Neck 109Colonic Neoplasms 109Uterine Cervical Neoplasms 106Stomach Neoplasms 102Recurrence 101Lymphoma 100Glioblastoma 90Lymphoma, Non-Hodgkin 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 78Hematologic Neoplasms 78Lymphoma, Follicular 77Urinary Bladder Neoplasms 76Parkinson Disease 4, Autosomal Dominant Lewy Body 74Glioma 72Sarcoma 70

Interventions

dalpiciclib 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × HR+/HER2- Advanced Breast Cancer × 1 year × Clear all
NCT05586841 2026-05-29

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â… b Study

Beijing 302 Hospital

Phase 1 Completed
22 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡